Search terms
Results 41 - 50 of 51 - ordered by :
Pages: 1 ... 1 2 3 4 5 6

Low awareness of heart failure among patients and the public is highlighted in surveys to be presented during Heart Failure 2019 the annual congress of the Heart Failure Association (HFA), a branch ...

Date : 06/05/2019

The EHRA White Book reports on the current status of arrhythmia treatments in the 55 ESC member countries (2) and has been published every year since 2008. Data is revealed on the use of ...

Date : 23/06/2013

The biggest developments include ablation of arrhythmogenic mechanisms and foci, the implantable cardioverter defibrillator (ICD) for primary and secondary prevention of sudden cardiac death, dual ...

Date : 21/06/2017

Rapid improvement in the socio-economic conditions of the Gulf states has been followed by lifestyle changes now contributing to high rates of cardiovascular disease. Around one in four Saudis has ...

Date : 16/02/2011

Asymptomatic or mildly symptomatic cardiac patients randomised to an implanted cardiac resynchronisation device with defibrillator (CRT-D) have a 34% lower risk of heart failure or death than those ...

Date : 01/09/2009

Artificial intelligence (AI) has shown promise to select heart failure patients for expensive treatments to prevent lethal arrhythmias, reports a study presented today at ICNC 2019. (1) The study is ...

Date : 13/05/2019

The ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 were developed by the European Society of Cardiology (ESC) in collaboration with the Heart Failure ...

Date : 25/08/2012

Traditionally, heart failure has been treated with drugs and weight control, but the advent of novel devices including implantable cardioverter defibrillators (ICDs), cardiac resynchronisation ...

Date : 20/03/2012

Sophia Antipolis, 18 July 2013: A joint consensus statement on the treatment of paediatric arrhythmias has been released by the European Heart Rhythm Association (EHRA) of the European Society of ...

Date : 18/07/2013

The results showed that, overall, there was no difference in the non-response to response conversion rate between MPP and BiV (31.8% vs 33.8%, p=0.72). “We had expected MPP to be better than ...

Date : 20/03/2018